# Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State

> **NCT05098262** · PHASE1 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DA-5210 10/500mg
- **DRUG:** DA-5210-R 10/500mg

## Key facts

- **NCT ID:** NCT05098262
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-31
- **Primary completion:** 2022-01-03
- **Final completion:** 2022-01-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098262, "Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fasting State". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05098262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*